SynthesisNPJ primary care respiratory medicine2026
The janus-faced role of uric acid in COPD: evidence from East Asians population.
Synthesis in NPJ primary care respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Uric acid as the final purine metabolite exhibits both antioxidative and proinflammatory properties. The association between uric acid and chronic obstructive pulmonary disease (COPD) remains ambiguous. This is particularly true within East Asian populations which lack comprehensive evidence. This study synthesizes data from 20 observational studies via a meta-analysis to compare uric acid levels in COPD patients and healthy controls. Furthermore, a two-sample Mendelian randomization (MR) approach was utilized, employing genome-wide association study (GWAS) data from East Asian populations to investigate the genetic causal relationship between uric acid and COPD. The meta-analysis demonstrated that uric acid concentrations in patients with COPD were significantly elevated compared to those in healthy controls (SMD = 1.57, 95% (CI): 1.11-2.02). This disparity was more pronounced in patients undergoing acute exacerbations and those with more severe airflow limitations. Conversely, MR analysis indicated that elevated uric acid levels were associated with a reduced risk of developing COPD (OR = 0.680, 95% CI: 0.543-0.852). The MR findings were corroborated through sensitivity analyses. Genetically predicted higher serum uric acid was causally associated with a lower risk of developing COPD in East Asians, whereas phenotypically elevated uric acid in patients with established COPD was associated with greater disease severity and exacerbation, suggesting distinct roles of uric acid in COPD susceptibility versus disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.